Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1520-1523

  Choi, Hyun Woo ^a   Shin, Jong Hee ^a   Jung, Sook In ^a   Park, Kyung Hwa ^a   Cho, Duck ^a   Kee, Seung Jung ^a   Shin, Myung Geun ^a   Suh, Soon Pal ^a   Ryang, Dong Wook ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; MICAFUNGIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BIOFILM; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE;

ANTIFUNGAL AGENTS; BIOFILMS; BLOOD; CANDIDA; CANDIDIASIS; FUNGAL PROTEINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; SPECIES SPECIFICITY;

EID: 34247111746     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01141-06     Document Type: Article

References (17)

1. Al-Fattani, M. A., and L. J. Douglas. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55:999-1008.
2. Al-Fattani, M. A., and L. J. Douglas. 2004. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 48:3291-3297.
3. Bachmann, S. P., K. VandeWalle, G. Ramage, T. F. Patterson, B. L. Wickes, J. R. Graybill, and J. L. Lopez-Ribot. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596.
4. Blumberg, H. M., W. R. Jarvis, J. M. Soucie, J. E. Edwards, J. E. Patterson, M. A. Pfaller, M. S. Rangel-Frausto, M. G. Rinaldi, L. Saiman, R. T. Wiblin, and R. P. Wenzel. 2001. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin. Infect. Dis. 33:177-186.
5. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Kojic, E. M., and R. O. Darouiche. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267.
7. Kuhn, D. M., and M. A. Ghannoum. 2004. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 5:186-197.
8. Kuhn, D. M., J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect. Immun. 70:878-888.
9. Kuhn, D. M., T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
10. Lewis, R. E., D. P. Kontoyiannis, R. O. Darouiche, I. I. Raad, and R. A. Prince. 2002. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrob. Agents Chemother. 46:3499-3505.
11. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davison, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Lavediere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Prioa, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
12. Parahitiyawa, N. B., Y. H. Samaranayake, L. P. Samaranayake, J. Ye, P. W. Tsang, B. P. Cheung, J. Y. Yau, and S. K. Yeung. 2006. Interspecies variation in Candida biofilm formation studied using the Calgary biofilm device. APMIS 114:298-306.
13. Pfaller, M. A., S. A. Messer, L. Boyken, R. J. Hollis, C. Rice, S. Tendolkar, and D. J. Diekema. 2004. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48:201-205.
14. Ramage, G., K. VandeWalle, S. P. Bachmann, B. L. Wickes, and J. L. Lopez-Ribot. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636.
15. Ramage, G., K. Vande Walle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
16. Shin, J. H., S. J. Kee, M. G. Shin, S. H. Kim, D. H. Shin, S. K. Lee, S. P. Suh, and D. W. Ryang. 2002. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J. Clin. Microbiol. 40:1244-1248.
17. Song, J. W., J. H. Shin, D. H. Shin, S. I. Jung, D. Cho, S. J. Kee, M. G. Shin, S. P. Suh, and D. W. Ryang. 2005. Differences in biofilm production by three genotypes of Candida parapsilosis from clinical sources. Med. Mycol. 43:657-661.